# Kanvas Biosciences

Source: https://onco.cc/companies/kanvas-biosciences/  
OnCo record `kanvas-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Kanvas maps which bacteria live in the gut and turns that knowledge into bacterial medicines that help cancer immunotherapy work better and treat its gut side effects.

## Summary

Kanvas Biosciences, headquartered at Monmouth Junction, New Jersey, with a West Coast site in South San Francisco, combines high-resolution spatial imaging of microbial communities with strain-resolved culturing and manufacturing to develop live biotherapeutic products. KAN-001 is a defined live biotherapeutic for non-small cell lung cancer intended to enhance response to immune checkpoint inhibitors, with preclinical data and manufacturing consistency presented in November 2025. KAN-004 is a metabolically complete live biotherapeutic for immune checkpoint inhibitor-induced colitis, for which a phase 1 trial was announced in March 2026. The company also offers microbiome research services and announced its own clinical manufacturing capabilities in 2025. In May 2026 Kanvas announced a USD 48 million Series A to bring its microbiome therapeutics to cancer patients; the Gates Foundation separately funds a malnutrition programme.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Monmouth Junction, NJ
- Type: biotech
- Website: https://www.kanvasbio.com

## Notes

- Series A investors not named on the fetched page; the Business Wire release itself was not fetched. Founding year not sourced.

## Sources

- Official website: https://www.kanvasbio.com
- News (Series A, KAN-004 phase 1): https://www.kanvasbio.com/news

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)

---
JSON: https://onco.cc/api/v1/entities/kanvas-biosciences.json